SUSAN GORSCHBOTH: Open Payments
NPI 1639722036 · ABINGDON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,042 in 64 payments from 16 companies in 2025. Trend: 2023 $632 · 2024 $1,238 · 2025 $1,042
Food & beverage: $1,042
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 15 | $188 |
| ABBVIE INC. | 13 | $160 |
| Astellas Pharma US Inc | 7 | $145 |
| Lilly USA, LLC | 8 | $136 |
| Exact Sciences Corporation | 3 | $69 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $65 |
| Amgen Inc. | 3 | $55 |
| PFIZER INC. | 2 | $44 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $40 |
| GlaxoSmithKline, LLC. | 2 | $33 |
Products named: Veozah, Ozempic, UBRELVY, VRAYLAR, The Cologuard Plus Collection Kit, MOUNJARO, XIFAXAN, OTEZLA.
Industry payments across MD — which companies pay providers there.
